Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet

Journal of Virological Methods

Volumn 141, Issue 2, 2007, Pages 212-215

  Ducancelle, Alexandra ^a   Alain, Sophie ^a,b   Petit, Françoise ^a   Sanson Le Pors, Marie José ^a   Mazeron, Marie Christine ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Cytomegalovirus; DNA polymerase; Foscarnet; Mutation; Resistance

Indexed keywords

DIGOXIGENIN; DNA POLYMERASE; FOSCARNET; NUCLEOTIDE;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SYNTHESIS; GENE INDUCTION; GENE MUTATION; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; MONITORING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SITE DIRECTED MUTAGENESIS; UL54 GENE; VALIDATION PROCESS; VIRUS GENE; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

ANTIVIRAL AGENTS; CATALYTIC DOMAIN; COLORIMETRY; CYTOMEGALOVIRUS; DIGOXIGENIN; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FOSCARNET; INHIBITORY CONCENTRATION 50; MUTATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VIRAL PROTEINS;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 33947496406     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2006.11.039     Document Type: Article

References (17)

1. Baldanti F., Underwood M.R., Stanat S.C., Biron K.K., Chou S., Sarasini A., Silini E., and Gerna G. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70 (1996) 1390-1395
2. Bonnet F., Lewden C., May T., Heripret L., Jougla E., Bevilacqua S., Costagliola D., Salmon D., Chene G., and Morlat P. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand. J. Infect. Dis. 37 (2005) 482-487
3. Chou S., Lurain N.S., Thompson K.D., Miner R.C., and Drew W.L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188 (2003) 32-34
4. Cihlar T., Fuller M.D., and Cherrington J.M. Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupled in vitro transcription/translation system. Protein Expres. Purif. 11 (1997) 209-218
5. Cihlar T., Fuller M.D., and Cherrington J.M. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72 (1998) 5927-5936
6. Ducancelle A., Belloc S., Alain S., Scieux C., Petit F., Sanson Le Pors M.-J., and Mazeron M.-C. Comparison of sequential cytomegalovirus isolates in a patient with lymphoma failing antiviral therapy. J. Clin. Virol. 29 (2004) 241-247
7. Ducancelle A., Gravisse J., Alain S., Petit F., Sanson Le Pors M.-J., and Mazeron M.-C. Phenotypic characterization of cytomegalovirus DNA polymerase: a tool to study cytomegalovirus isolates resistant to foscarnet. J. Virol. Meth. 125 (2005) 145-151
8. Ducancelle A., Champier G., Alain S., Petit F., Sanson Le Pors M.-J., and Mazeron M.-C. Novel mutation in the UL54 gene of human cytomegalovirus isolates conferring resistance to foscarnet. Antiviral Ther. 11 (2006) 537-540
9. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12 (1999) 286-297
10. Gilbert C., and Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49 (2005) 873-883
11. Hodson E.M., Jones C.A., Webster A.C., Strippoli G.F., Barclay P.G., Kable K., Vimalachandra D., and Craig J.C. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365 (2005) 2105-2115
12. Mousavi-Jazi M., Schloss L., Drew W.L., Linde A., Miner R.C., Harmenberg J., Wahren B., and Brytting M. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J. Clin. Virol. 23 (2001) 1-15
13. Salmon-Céron D., Mazeron M.C., Chaput S., Boukli N., Sénéchal B., Houhou N., Katlama C., Matheron S., Fillet A.M., Gozlan J., Leport C., Jeantils V., Freymuth F., and Costagliola D. Plasma cytomegalovirus DNA, pp65 antigenemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS 14 (2000) 1041-1049
14. Teo I.A., Griffin B.E., and Jones M.D. Characterization of the DNA polymerase gene of herpesvirus 6. J. Virol. 65 (1991) 4670-4680
15. Ye L.B., and Huang E.S. In vitro expression of the human cytomegalovirus DNA polymerase gene: effects of sequence alterations on enzyme activity. J. Virol. 67 (1993) 6339-6347
16. Zamora, M.R., Davis, R.D., Leonard, C., for the CMV Advisory Board Expert Committee, 2005. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 80, 545.
17. Zandberg M., deMaar E.F., Hofker H.S., van der Heide J.J.H., Rosati S., and van Son W.J. Initial cytomegalovirus prophylaxis with ganciclovir: no guarantee for prevention of late serious manifestations of CMV after solid organ transplantation. Neth. J. Med. 63 (2005) 408-412